| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Systemic spread is an early step in breast cancer.
|
Cancer Cell
|
2008
|
7.91
|
|
2
|
A pooled analysis of bone marrow micrometastasis in breast cancer.
|
N Engl J Med
|
2005
|
6.86
|
|
3
|
Circulating tumor cells in patients with breast cancer dormancy.
|
Clin Cancer Res
|
2004
|
4.48
|
|
4
|
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.
|
J Clin Oncol
|
2013
|
4.28
|
|
5
|
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
|
N Engl J Med
|
2012
|
4.24
|
|
6
|
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
|
Lancet Oncol
|
2013
|
3.92
|
|
7
|
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.
|
Breast Cancer Res
|
2009
|
3.76
|
|
8
|
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
|
J Clin Oncol
|
2011
|
3.45
|
|
9
|
HER-2 gene amplification can be acquired as breast cancer progresses.
|
Proc Natl Acad Sci U S A
|
2004
|
3.43
|
|
10
|
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
|
Clin Cancer Res
|
2010
|
2.66
|
|
11
|
Treatment of breast cancer during pregnancy: an observational study.
|
Lancet Oncol
|
2012
|
2.38
|
|
12
|
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
|
Cancer Res
|
2006
|
2.36
|
|
13
|
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
|
Cancer Metastasis Rev
|
2013
|
1.82
|
|
14
|
Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma.
|
BMC Cancer
|
2011
|
1.74
|
|
15
|
Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
|
Breast Cancer Res
|
2012
|
1.62
|
|
16
|
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.
|
Clin Cancer Res
|
2011
|
1.56
|
|
17
|
The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells.
|
Menopause
|
2011
|
1.52
|
|
18
|
Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy.
|
Menopause
|
2013
|
1.39
|
|
19
|
SOX2 expression associates with stem cell state in human ovarian carcinoma.
|
Cancer Res
|
2013
|
1.34
|
|
20
|
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
|
Eur J Cancer
|
2013
|
1.26
|
|
21
|
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study.
|
Cytometry B Clin Cytom
|
2010
|
1.24
|
|
22
|
Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy.
|
Breast Cancer Res Treat
|
2005
|
1.24
|
|
23
|
Changes in tumour biological markers during primary systemic chemotherapy (PST).
|
Anticancer Res
|
2008
|
1.23
|
|
24
|
Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.
|
Gynecol Oncol
|
2011
|
1.22
|
|
25
|
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
|
Breast Cancer Res
|
2012
|
1.21
|
|
26
|
Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast.
|
Breast Cancer Res Treat
|
2011
|
1.17
|
|
27
|
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.
|
Clin Cancer Res
|
2013
|
1.15
|
|
28
|
Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma--evaluation by using antimüllerian hormone and retrieved oocytes.
|
Fertil Steril
|
2012
|
1.10
|
|
29
|
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
|
Hum Pathol
|
2012
|
1.08
|
|
30
|
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.
|
Breast Cancer Res
|
2008
|
1.07
|
|
31
|
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients.
|
Proc Natl Acad Sci U S A
|
2013
|
1.02
|
|
32
|
Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer.
|
Anticancer Res
|
2011
|
1.01
|
|
33
|
Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients.
|
Breast Cancer Res Treat
|
2007
|
0.99
|
|
34
|
Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer.
|
Mol Oncol
|
2012
|
0.99
|
|
35
|
Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection.
|
Electrophoresis
|
2006
|
0.98
|
|
36
|
Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.
|
Anticancer Res
|
2011
|
0.97
|
|
37
|
SOX2 expression and prognostic significance in ovarian carcinoma.
|
Int J Gynecol Pathol
|
2013
|
0.93
|
|
38
|
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
|
Breast Cancer Res
|
2011
|
0.93
|
|
39
|
The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.92
|
|
40
|
Clinical Recommendations of DEGRO and AGO on Preferred Standard Palliative Radiotherapy of Bone and Cerebral Metastases, Metastatic Spinal Cord Compression, and Leptomeningeal Carcinomatosis in Breast Cancer.
|
Breast Care (Basel)
|
2010
|
0.92
|
|
41
|
Evaluation of a RT-PCR based routine screening tool for the detection of disseminated epithelial cells in the bone marrow of breast cancer patients.
|
Breast Cancer Res Treat
|
2008
|
0.91
|
|
42
|
Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignancies.
|
Int J Gynecol Cancer
|
2009
|
0.91
|
|
43
|
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
|
BMC Cancer
|
2011
|
0.90
|
|
44
|
Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling.
|
BMC Biochem
|
2007
|
0.90
|
|
45
|
Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients.
|
Clin Chem
|
2013
|
0.89
|
|
46
|
HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor.
|
Anticancer Res
|
2009
|
0.89
|
|
47
|
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
|
Mol Oncol
|
2013
|
0.88
|
|
48
|
Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery.
|
Breast Cancer Res Treat
|
2002
|
0.87
|
|
49
|
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy.
|
Virchows Arch
|
2011
|
0.86
|
|
50
|
Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
|
Anticancer Res
|
2008
|
0.86
|
|
51
|
Acute twin-twin transfusion syndrome: a case report.
|
J Reprod Med
|
2007
|
0.86
|
|
52
|
Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients.
|
Anticancer Res
|
2005
|
0.86
|
|
53
|
International study on inter-reader variability for circulating tumor cells in breast cancer.
|
Breast Cancer Res
|
2014
|
0.86
|
|
54
|
Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
|
Gynecol Oncol
|
2007
|
0.85
|
|
55
|
Oncolytic virotherapy of gynecologic malignancies.
|
Gynecol Oncol
|
2010
|
0.85
|
|
56
|
Oncolytic virotherapy of breast cancer.
|
Gynecol Oncol
|
2011
|
0.85
|
|
57
|
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies.
|
Breast Cancer Res Treat
|
2014
|
0.85
|
|
58
|
Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
|
Breast Cancer Res Treat
|
2013
|
0.84
|
|
59
|
HER2-positive DTCs/CTCs in breast cancer.
|
Recent Results Cancer Res
|
2012
|
0.84
|
|
60
|
Optimal treatment for patients with ectopic pregnancies and a history of fertility-reducing factors.
|
Arch Gynecol Obstet
|
2009
|
0.84
|
|
61
|
Circulating tumour cells in breast cancer.
|
Ecancermedicalscience
|
2013
|
0.84
|
|
62
|
Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer.
|
Anticancer Res
|
2013
|
0.83
|
|
63
|
Circulating tumor cells in breast cancer.
|
Clin Chim Acta
|
2013
|
0.83
|
|
64
|
Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer.
|
Breast Cancer Res Treat
|
2014
|
0.83
|
|
65
|
Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits.
|
Dtsch Arztebl Int
|
2014
|
0.83
|
|
66
|
Time is an important factor when processing samples for the detection of disseminated tumor cells in blood/bone marrow by reverse transcription-PCR.
|
Clin Chem
|
2004
|
0.82
|
|
67
|
Pregnancy after successful cancer treatment: what needs to be considered?
|
Onkologie
|
2012
|
0.81
|
|
68
|
Meconium-stained amniotic fluid--perinatal outcome and obstetrical management in a low-risk suburban population.
|
Eur J Obstet Gynecol Reprod Biol
|
2006
|
0.81
|
|
69
|
Influence of pregnancy on bone density: a risk factor for osteoporosis? Measurements of the calcaneus by ultrasonometry.
|
Arch Gynecol Obstet
|
2011
|
0.81
|
|
70
|
Number of hysteroscopies and the time interval between hysteroscopy and surgery: influence on peritoneal cytology in patients with endometrial cancer.
|
Anticancer Res
|
2010
|
0.80
|
|
71
|
Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
|
Oncol Rep
|
2010
|
0.80
|
|
72
|
Pregnancy after breast cancer: case report and review of the literature.
|
Arch Gynecol Obstet
|
2011
|
0.80
|
|
73
|
ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.
|
Invest New Drugs
|
2009
|
0.79
|
|
74
|
Prevalence and prognostic value of disseminated tumor cells in primary endometrial, cervical and vulvar cancer patients.
|
Future Oncol
|
2014
|
0.79
|
|
75
|
Oestetrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: comparison of four oestrogens.
|
Eur J Contracept Reprod Health Care
|
2014
|
0.79
|
|
76
|
A laminin-rich basement membrane matrix influences estrogen receptor beta expression and morphology of MDA-MB-231 breast cancer cells.
|
Oncol Rep
|
2009
|
0.79
|
|
77
|
Clinical implications of the detection of circulating tumor cells in breast cancer patients.
|
Biomark Med
|
2012
|
0.79
|
|
78
|
The role of smooth muscle in the pathogenesis of pelvic organ prolapse--an immunohistochemical and morphometric analysis of the cervical third of the uterosacral ligament.
|
Int Urogynecol J Pelvic Floor Dysfunct
|
2007
|
0.79
|
|
79
|
Cytotoxic effect of conjugates of doxorubicin and human chorionic gonadotropin (hCG) in breast cancer cells.
|
Breast Cancer Res Treat
|
2003
|
0.79
|
|
80
|
Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situ.
|
Breast Cancer Res Treat
|
2014
|
0.78
|
|
81
|
Proteomic expression profiling of breast cancer.
|
Recent Results Cancer Res
|
2007
|
0.78
|
|
82
|
Image analysis systems for the detection of disseminated breast cancer cells on bone-marrow cytospins.
|
J Clin Lab Anal
|
2005
|
0.78
|
|
83
|
Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1.
|
Maturitas
|
2013
|
0.78
|
|
84
|
Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer.
|
Prostate
|
2015
|
0.78
|
|
85
|
Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned.
|
Langenbecks Arch Surg
|
2011
|
0.78
|
|
86
|
Small cell carcinoma of vulva: curative multimodal treatment in face of resistance to initial standard chemotherapy.
|
Strahlenther Onkol
|
2010
|
0.77
|
|
87
|
Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years.
|
Anticancer Res
|
2003
|
0.77
|
|
88
|
The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
|
Int J Gynecol Cancer
|
2015
|
0.77
|
|
89
|
Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread.
|
Breast Cancer Res Treat
|
2011
|
0.77
|
|
90
|
Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells.
|
Gynecol Endocrinol
|
2012
|
0.76
|
|
91
|
Lower extremity compartment syndrome after laparoscopic radical hysterectomy: brief report of an unusual complication of laparoscopic positioning requirements.
|
J Minim Invasive Gynecol
|
2011
|
0.76
|
|
92
|
Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity.
|
Am J Obstet Gynecol
|
2004
|
0.76
|
|
93
|
Management of fertility preservation in young breast cancer patients in a large breast cancer centre.
|
Arch Gynecol Obstet
|
2010
|
0.76
|
|
94
|
The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
|
Breast Cancer Res
|
2013
|
0.76
|
|
95
|
Mammotome versus ATEC: a comparison of two breast vacuum biopsy techniques under sonographic guidance.
|
Arch Gynecol Obstet
|
2009
|
0.76
|
|
96
|
Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer.
|
Menopause
|
2016
|
0.76
|
|
97
|
Knock down of p53 or its ubiquitin ligase E6AP does not affect the sensitivity of human papillomavirus-positive cervical cancer cells to cisplatin.
|
Am J Cancer Res
|
2012
|
0.75
|
|
98
|
Correction: EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
|
PLoS One
|
2016
|
0.75
|
|
99
|
Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases.
|
Prostate
|
2012
|
0.75
|
|
100
|
Recovery of residual curarization after red blood cell transfusion.
|
Med Sci Monit
|
2012
|
0.75
|
|
101
|
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
|
Invest New Drugs
|
2011
|
0.75
|
|
102
|
Fertility preservation in young female lymphoma patients: review of available options and initial experiences with their implementation in clinical routine.
|
Onkologie
|
2011
|
0.75
|
|
103
|
Fertility conservation in breast cancer patients.
|
Womens Health (Lond Engl)
|
2011
|
0.75
|
|
104
|
[Detection of disseminated tumor cells in the bone marrow of breast cancer patients with a new molecular method].
|
Ginekol Pol
|
2012
|
0.75
|
|
105
|
New insight on a possible mechanism of progestogens in terms of breast cancer risk.
|
Horm Mol Biol Clin Investig
|
2011
|
0.75
|
|
106
|
Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients.
|
Breast Cancer Res Treat
|
2015
|
0.75
|
|
107
|
Abnormal cytology during pregnancy--a retrospective analysis of patients in a dysplasia clinic.
|
Anticancer Res
|
2013
|
0.75
|
|
108
|
Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells.
|
Gynecol Endocrinol
|
2012
|
0.75
|
|
109
|
Development of a gel-simulation model and generation of standard tables for the complete extirpation of benign breast lesions with vacuum assisted biopsy under ultrasound guidance.
|
Ultrasound Med Biol
|
2006
|
0.75
|
|
110
|
Liquid Biopsy in Metastasized Breast Cancer as Basis for Treatment Decisions.
|
Oncol Res Treat
|
2016
|
0.75
|
|
111
|
Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7).
|
Int J Gynecol Cancer
|
2016
|
0.75
|